Serum markers for early diagnosis of fulminant type 1 diabetes
Project/Area Number |
15K09402
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Metabolomics
|
Research Institution | Osaka Medical College |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
佐野 寛行 大阪医科大学, 医学部, 助教 (20556435)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 劇症1型糖尿病 / 抗CD300e抗体 / Seromic analysis / 抗CD300e抗体 / Seromic analysis / 抗CD300e抗体 / 新規抗体 |
Outline of Final Research Achievements |
The present study clarified a novel biomarker anti-CD300e antibody to diagnose fulminant type 1 diabetes (FT1D). Seromic analysis revealed 9 antibodies which showed high signals in sera from patients with FT1D in acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in acute phase than that in autoimmune type 1 diabetes (T1AD), type 2 diabetes (T2D), autoimmune thyroid disease (AITD) patients and healthy controls (HC) by ELISA.
|
Report
(4 results)
Research Products
(3 results)
-
[Journal Article] Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.2016
Author(s)
Haseda F, Imagawa A, Nishikawa H, Mitsui S, Tsutsumi C, Fujisawa R, Sano H, Murase-Mishiba Y, Terasaki J, Sakaguchi S, Hanafusa T.
-
Journal Title
PLOS ONE
Volume: 11
Issue: 8
Pages: e0160576-e0160576
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-